Callender VD, Alexis AF, Gold LFS, et al. - In this investigation, researchers tested the safety and effectiveness of crisaborole ointment, 2%, depending on race [Asian/native Hawaiian/other Pacific Islander, black/African American, and other/American Indian/Alaskan native] and ethnicity [Hispanic/Latino or not Hispanic/Latino] for the treatment of mild-to-moderate atopic dermatitis (AD) in individuals aged ≥ 2 years. In the pivotal trials, the frequency of crisaborole-related adverse events was 7.1–8.5%. Regardless of race or ethnicity, in patients aged ≥ 2 years with mild-to-moderate AD, crisaborole improved global disease severity. Crisaborole has been effective in decreasing AD signs prevalent in patients with color skin and has been associated with low frequency treatment-related treatment-emergent adverse events, indicating that crisaborole may be a suitable treatment choice for these patients.